Humeira Badsha1 , Kok Ooi Kong2 and Paul P. Tak1, 3
(1)
Dubai Bone & Joint Center LLC, Level 50, Emirates Towers, P.O. Box 118855, Dubai, United Arab Emirates
(2)
Department of Rheumatology, Allergy and Immunology, Tan Tock Seng Hospital, Singapore, Singapore
(3)
Division of Clinical Immunology & Rheumatology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
Received: 12 September 2007 Revised: 10 October 2007 Accepted: 14 October 2007 Published online: 1 November 2007
Abstract Studies have shown that patients with rheumatoid arthritis (RA) in the Middle East have delayed diagnosis and low disease-modifying anti-rheumatic drug (DMARD) utilization. We describe the characteristics and treatments of consecutive RA patients presenting to a new musculoskeletal clinic in Dubai, United Arab Emirates (UAE). Demographic and clinical data were collected over a 10-month period at the first visit to our clinic for patients meeting the American College of Rheumatology (ACR) criteria for RA. A total of 100 patients were seen: (average ± SD) age 42.2 ± 12.3 years; female 87%; Arabs 38%, Indian 36%, Caucasian and others 26%; 73% rheumatoid-factor positive; years since diagnosis: 3.9 ± 5.7; lag time between symptom onset to diagnosis 1.2 ± 1.3 years and lag time to first DMARD was 1.6 ± 2.0 years. Mean tender joint count was 8.9 ± 7.9, mean swollen joint count 9.0 ± 7.6, mean patient’s global assessment of disease activity 57.4 ± 25.0 mm, mean ESR 33 ± 25 mm/h, mean DAS28 5.2 ± 1.6, physician global assessment 55.0 ± 23.8. Only 43% were on DMARDs (25% MTX, 5% TNF blockers). Among the patients who were not on DMARD, only 28.1% had disease duration less than 1 year (p = <0.01). Erosions were present in 55.2% of patients with available X-rays, and deformities in 26% of patients. There were no racial differences in disease characteristics. The UAE has a unique population with many races residing in the country. Among the first 100 consecutive patients seen at our clinic, there were no significant differences in disease characteristics with the majority of the patients having very active disease, delayed diagnosis, and not being treated with DMARDs.
Keywords Arab - Disease activity - Gulf - Indian - Middle East - Rheumatoid arthritis - Treatment
Footline: RA in the United Arab Emirates
Humeira BadshaEmail: humeira.badsha@dbaj.ae
References
1.
Al-Rawi ZS, Alazzawi AJ, Alajili FM, Alwakil R (1978) Rheumatoid arthritis in population samples in Iraq. Ann Rheum Dis 37(1):73–75, Feb 1978
2.
Al-Salem IH, Al-Awadhi AM (2004) The expression of rheumatoid arthritis in Kuwaiti patients in an outpatient hospital-based practice. Med Princ Pract 13(1):47–50, Jan 2004
3.
Al Attia HM, Gatee OB, George S, Masri MM (1993) Rheumatoid arthritis in a population sample in the Gulf: clinical observations. Clin Rheumatol 12(4):506–510, Dec 1993
4.
Alballa SR (1995) The expression of rheumatoid arthritis in Saudi Arabia. Clin Rheumatol 14(6):641–645, Nov 1995
5.
Badsha H, Kong KO, Tak PP (2007) Rheumatoid arthritis in Dubai-delayed diagnosis and low usage of disease modifying antirheumatic drugs. Ann Rheum Dis 66(6):835, Jun 2007
6.
Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31(3):315–324, Mar 1988
7.
Smolen JS, Breedveld FC, Schiff MH, Kalden JR, Emery P, Eberl G et al (2003) A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology (Oxford) 42(2):244–257, Feb 2003
8.
Prevoo ML, van ’t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL (1995) Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38(1):44–48, 1995 Jan
9.
Sokka T, Kautiainen H, Toloza S, Makinen H, Verstappen SM, Hetland ML et al (2007) QUEST-RA: Quantitative clinical assessment of patients with rheumatoid arthritis seen in standard rheumatology care in 15 countries. Ann Rheum Dis 66:1491–1496, Apr 2007
10.
Michaud K, Wolfe F (2006) Trends in mEdication Use by 10,982 Rheumatoid Arthritis patients in the United States from 1998–2005: Biological Use now at 40%. Ann Rheum Dis 65(Suppl II):311
11.
Nurmohamed MT, Dijkmans BA (2005) Efficacy, tolerability and cost effectiveness of disease-modifying antirheumatic drugs and biologic agents in rheumatoid arthritis. Drug 65(5):661–694
12.
Verstappen SM, Jacobs JW, Bijlsma JW, Heurkens AH, van Booma-Frankfort C, Borg EJ et al (2003) Five-year followup of rheumatoid arthritis patients after early treatment with disease-modifying antirheumatic drugs versus treatment according to the pyramid approach in the first year. Arthritis Rheum 48(7):1797–1807, Jul 2003
13.
Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, van Vollenhoven R et al (2006) The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 54(1):26–37, Jan 2006
14.
Michaud K, Wolfe F (2005) Reduced Mortality among RA Patients Treated with Anti-TNF Therapy and Methotrexate. Ann Rheum Dis 64(Suppl III):87, 2006
15.
St Clair EW, Van der Heijde DM, Smolen JS, Maini RN, Bathon JM, Emery P et al (2004) Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 50(11):3432–3443, Nov 2004
16.
Anderson JJ, Wells G, Verhoeven AC, Felson DT (2000) Factors predicting response to treatment in rheumatoid arthritis: the importance of disease duration. Arthritis Rheum 43(1):22–29, Jan 2000
17.
Pountain G (1991) The prevalence of rheumatoid arthritis in the Sultanate of Oman. Br J Rheumatol 30(1):24–28, Feb 1991
18.
Malaviya AN, Kapoor SK, Singh RR, Kumar A, Pande I (1993) Prevalence of rheumatoid arthritis in the adult Indian population. Rheumatol Int 13(4):131–134
19.
Lacaille D, Anis AH, Guh DP, Esdaile JM (2005) Gaps in care for rheumatoid arthritis: a population study. Arthritis Rheum 3(2):241–248, Apr 15, 2005
20.
Stucki G (1997) Specialist management: needs and benefits. Baillieres Clin Rheumatol 11(1):97–107, Feb 1997
21.
Chandrashekara S, Anilkumar T, Jamuna S (2002) Complementary and alternative drug therapy in arthritis. J Assoc Physicians India 50:225–227, Feb 2002
22.
Abdel-Nasser AM, Rasker JJ, Valkenburg HA (1997) Epidemiological and clinical aspects relating to the variability of rheumatoid arthritis. Semin Arthritis Rheum 27(2):123–140, Oct 1997
Popular Posts
-
Dr. Humeira Badsha Medical center, Beach Park Plaza , Jumeira Beach Road Next to Neurospinal hospital. Phone +9714-3856009. Email info@dr...
-
Methotrexate is commonly prescribed and effectively used to treat rheumatoid arthritis and other rheumatic conditions . Methotrexate has t...
-
Yesterday I saw a lovely lady from the UK. She has been seeing her GP in the NHS system for many months with severe back pain radiating to ...
-
Articles - Peer Reviewed: 1. Badsha H, Gunes B, Grossman J, Brahn E. Troponin I assessment of cardiac involvement in patients with con...
-
Patients in Dubai still have a really hard time finding the right doctors for a variety of conditions. The right Specialists exist and usua...
-
PHILADELPHIA -- Milnacipran (Savella) improved pain and mental functioning in patients suffering from fibromyalgia, researchers said here. ...
-
I see many patients in Dubai whose fibromyalgia is not recognized or diagnosed for years. What Is Fibromyalgia? Fibromyalgia is a common con...
-
Being a Rheumatologist in the UAE is a unique experience. Most of my patients have had 3, 4 opinions for their disease, finding no solution...
-
UAE Residents Need to Get Out in the Sun More 24 May 2007 High Level of Osteopenia and Osteoporosis detected in recent screening programmes ...
No comments:
Post a Comment